Mavacamten induces a clinical, hemodynamic, and biomarker response beyond the primary endpoint in EXPLORER-HCM: results from a post hoc machine learning analysis

Back

ESC Professional Premium Access

Mavacamten induces a clinical, hemodynamic, and biomarker response beyond the primary endpoint in EXPLORER-HCM: results from a post hoc machine learning analysis

Session: Hypertrophic cardiomyopathy: not so rare, but not so easy

Topic: Hypertrophic Cardiomyopathy

Speaker: Professor I. Olivotto (Florence, IT)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Professor Iacopo Olivotto

University of Florence, Florence (Italy)

31 presentations

16 followers

4 more presentations in this session

Metoprolol improves left ventricular longitudinal function at rest and during exercise in obstructive hypertrophic cardiomyopathy

Speaker: Mrs A. Dybro (Aarhus, DK)

Prevalence and clinical correlates of clinical red flags for rare diseases in consecutive patients presenting with HCM phenotype

Speaker: Doctor N. Maurizi (Lausanne, CH)

Temporal trends, characteristics and comorbidities of patients with hypertrophic cardiomyopathy in denmark from 2005-2018: A nationwide cohort study.

Speaker: Doctor C. Zoerner (Copenhagen, DK)

Representativeness of EXPLORER-HCM trial and prevalence of eligibility criteria for Mavacamten in a nationwide cohort

Speaker: Doctor M. Brandao (Vila Nova de Gaia, PT)

Access the full session

Hypertrophic cardiomyopathy: not so rare, but not so easy

Speakers: Professor I. Olivotto, Mrs A. Dybro, Doctor N. Maurizi, Doctor C. Zoerner, Doctor M. Brandao

Access

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources